# Maurizio Cutolo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maurizio-cutolo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,267 |
| Field | Systemic Sclerosis and Related Diseases |
| h-index | 109 |
| i10-index | 544 |
| Last Known Institution | Ospedale Policlinico San Martino |
| OpenAlex ID | https://openalex.org/A5028547482 |
| ORCID iD | https://orcid.org/0000-0002-5396-0932 |
| Works | 1,148 |

## Researcher papers

- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-2/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-3/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation](https://scholariq.org/papers/the-eular-points-to-consider-for-use-of-antirheumatic-drugs-before-pregnancy-and/)
- [European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update](https://scholariq.org/papers/european-league-against-rheumatism-eular-recommendations-for-the-management-of/)
- [Mapping and predicting mortality from systemic sclerosis](https://scholariq.org/papers/mapping-and-predicting-mortality-from-systemic-sclerosis/)
- [Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs](https://scholariq.org/papers/phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550-or/)
- [European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes](https://scholariq.org/papers/european-dermatology-forum-s1-guideline-on-the-diagnosis-and-treatment-of/)

## Researcher topics

- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Dermatologic Treatments and Research](https://scholariq.org/topics/dermatologic-treatments-and-research/)
- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)

## Researcher university

- [Ospedale Policlinico San Martino](https://scholariq.org/institutions/ospedale-policlinico-san-martino/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.